Among the attempts to target the actionable mutations in CRC, the treatment with anti-HER2 in patients carrying Erbb2 amplification has been successful in clinical trials, whereas patients with BrafV600E-mutant CRC are poorly responsive to the administration of vemurafenib or dabrafenib.13 40. Here, ERBB2 is linked to colorectal carcinoma.